Home Cart 0 Sign in  

[ CAS No. 1029684-37-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1029684-37-4
Chemical Structure| 1029684-37-4
Structure of 1029684-37-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1029684-37-4 ]

Related Doc. of [ 1029684-37-4 ]

Alternatived Products of [ 1029684-37-4 ]

Product Details of [ 1029684-37-4 ]

CAS No. :1029684-37-4 MDL No. :MFCD11100960
Formula : C14H23BN2O3 Boiling Point : -
Linear Structure Formula :- InChI Key :BVIWGBKKGPHNAB-UHFFFAOYSA-N
M.W : 278.16 Pubchem ID :24880008
Synonyms :

Calculated chemistry of [ 1029684-37-4 ]

Physicochemical Properties

Num. heavy atoms : 20
Num. arom. heavy atoms : 5
Fraction Csp3 : 0.79
Num. rotatable bonds : 2
Num. H-bond acceptors : 4.0
Num. H-bond donors : 0.0
Molar Refractivity : 78.16
TPSA : 45.51 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.72 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 1.8
Log Po/w (WLOGP) : 1.56
Log Po/w (MLOGP) : 0.58
Log Po/w (SILICOS-IT) : 0.86
Consensus Log Po/w : 0.96

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.75
Solubility : 0.493 mg/ml ; 0.00177 mol/l
Class : Soluble
Log S (Ali) : -2.37
Solubility : 1.17 mg/ml ; 0.00422 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.9
Solubility : 0.346 mg/ml ; 0.00124 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 4.16

Safety of [ 1029684-37-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1029684-37-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1029684-37-4 ]

[ 1029684-37-4 ] Synthesis Path-Downstream   1~20

  • 1
  • [ 872-31-1 ]
  • [ 1029684-37-4 ]
  • C12H14N2OS [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 2
  • [ 3034-53-5 ]
  • [ 1029684-37-4 ]
  • C11H13N3OS [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 3
  • [ 626-55-1 ]
  • [ 1029684-37-4 ]
  • [ 1029684-39-6 ]
YieldReaction ConditionsOperation in experiment
36% With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 4
  • [ 1029684-36-3 ]
  • [ 1029684-37-4 ]
YieldReaction ConditionsOperation in experiment
82% With hydrogen In methanol at 0 - 20℃; for 2h;
  • 5
  • [ 108-86-1 ]
  • [ 1029684-37-4 ]
  • C14H16N2O [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 6
  • [ 1029684-37-4 ]
  • [ 766-85-8 ]
  • C15H18N2O2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 7
  • [ 1029684-37-4 ]
  • [ 106-38-7 ]
  • C15H18N2O [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 8
  • [ 1029684-37-4 ]
  • [ 615-41-8 ]
  • C14H15ClN2O [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 9
  • [ 1029684-37-4 ]
  • [ 696-62-8 ]
  • [ 1029684-38-5 ]
YieldReaction ConditionsOperation in experiment
66% With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 10
  • [ 1029684-37-4 ]
  • [ 2042-37-7 ]
  • C15H15N3O [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 11
  • [ 1029684-37-4 ]
  • [ 1829-28-3 ]
  • C17H20N2O3 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 12
  • [ 1029684-37-4 ]
  • [ 6091-64-1 ]
  • C17H20N2O3 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 13
  • [ 1029684-37-4 ]
  • [ 6630-33-7 ]
  • C15H16N2O2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide Heating;
  • 14
  • [ 1029684-37-4 ]
  • [ 1282512-46-2 ]
  • [ 1282512-94-0 ]
YieldReaction ConditionsOperation in experiment
17% With copper(l) iodide; cesium fluoride In N,N-dimethyl-formamide at 130℃; for 0.666667h; Microwave irradiation; 242 Example 242 (2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-9-(1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 242 1-(Tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole was prepared by hydrogen with palladium reduction of 2-chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole. To a mixture of 9-bromo-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 250 mg, 0.67 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole (204 mg, 0.73 mmol) in dry DMF (2.5 mL) under nitrogen was added CsF (254 mg, 1.68 mmol), CuI (13 mg, 0.067 mmol) and Pd(PPh3)4 (39 mg, 0.034 mmol). The reaction mixture was heated at 130° C. for 40 min under microwave. Cooled to room temperature, the resulting mixture was poured into water and extracted with EtOAc. Dried organics over sodium sulfate and purified by pre-TLC (100% EtOAc) to give 242 as a yellow solid (49.3 mg, yield: 17%). 1H NMR (DMSO-d6, 400 MHz): δ8.49 (d, J=8.4 Hz, 1H), 8.11 (s, 1H), 7.97 (s, 1H), 7.92 (s, 1H), 7.28 (dd, J1=1.6 Hz, J2=8.4 Hz, 1H), 7.18 (d, J=6.8 Hz, 2H), 5.92-5.89 (m, 1H), 5.19 (d, J=9.2 Hz, 1H), 4.55-4.52 (m, 4H), 4.04 (d, J=11.2 Hz, 1H), 3.60-3.56 (m, 1H), 2.29-1.90 (m, 3H), 1.58-1.48 (m, 9H). MS: (ESI, m/z)=446 [M+H]+
  • 15
  • [ 1029684-37-4 ]
  • tert-butyl 4-(10-bromo-2-oxo-1,2-dihydropyrimido[1,2-b]indazol-4-yl)piperidine-1-carboxylate [ No CAS ]
  • tert-butyl 4-{12-oxo-10-[1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl]-1,2-dihydropyrimido[1,2-b]indazol-4-yl}piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
25% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate In water; N,N-dimethyl-formamide at 80℃; for 16h; 182A tert-butyl 4- { 2-oxo- 10-[ 1 -(tetrahydro-2H-pyran-2-yl)- 1 H-imidazol-5-yl] - 1 ,2-dihydropyrimido[ 1 ,2- b] indazol-4-yl Jpiperidine- 1 -carboxylate tert-butyl 4-( 10-bromo-2-oxo- 1 ,2-dihydropyrimido[ 1 ,2-b] indazol-4-yl)piperidine- 1 -carboxylate (200 mg, 0.45 mmol) and l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- imidazole (187 mg, 0.67 mmol) were dissolved in N,N-Dimethylformamide (5 ml) and treated with sodium carbonate solution (2M in water, 0.89 ml). After degassing the solution 1,1 '- Bis(diphenylphosphino)ferrocene-palladium(II)chloride (16.4 mg, 0.02 mmol) was added. After stirring at 80°C for 16 h, the mixture was separated via reverse phase HPLC (gradient acetonitrile/water with 0.1 % trifluoroacetic acid) which afforded the title compound (55.4 mg, 25% of theory). LC-MS (Method 5B): Rt = 0.84 min, MS (ESIPos): m z = 519.5 [M+H]+
55.4 mg With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate In water; N,N-dimethyl-formamide at 80℃; for 16h; 182.A tert-butyl 4-{12-oxo-10-[1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl]-1,2-dihydropyrimido[1,2-b]indazol-4-yl}piperidine-1-carboxylate Example 182A tert-butyl 4-{12-oxo-10-[1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl]-1,2-dihydropyrimido[1,2-b]indazol-4-yl}piperidine-1-carboxylate tert-butyl 4-(10-bromo-2-oxo-1,2-dihydropyrimido[1,2-b]indazol-4-yl)piperidine-1-carboxylate (200 mg, 0.45 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole (187 mg, 0.67 mmol) were dissolved in N,N-Dimethylformamide (5 ml) and treated with sodium carbonate solution (2M in water, 0.89 ml). After degassing the solution 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)chloride (16.4 mg, 0.02 mmol) was added. After stirring at 80° C. for 16 h, the mixture was separated via reverse phase HPLC (gradient acetonitrile/water with 0.1% trifluoroacetic acid) which afforded the title compound (55.4 mg, 25% of theory). LC-MS (Method 5B): Rt=0.84 min, MS (ESIPos): m/z=519.5 [M+H]+
  • 16
  • [ 1029684-37-4 ]
  • C20H18BrF2N3O2 [ No CAS ]
  • C28H29F2N5O3 [ No CAS ]
YieldReaction ConditionsOperation in experiment
39% With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In 1,4-dioxane; water at 95℃; Inert atmosphere; A17 Preparation of intermediate 58 A solution of compound 277 (282 mg; 0.63 mmol), 1-(tetrahydro-2H-pyran-2-yl)-5- (4,4,5,5 -tetramethyl- 1,3 ,2-dioxaborolan-2-yl)- 1 H-imidazo le (226 mg; 0.81 mmo 1) and K2C03 (173 mg; 1.25 mmol) in 1,4-dioxane (4.27 mL) and water (0.64 mL) was degassed under N2. Pd.C12(dppf).DCM (51 mg; 62.6 jimol) was added and the reaction mixture was heated at 95°C overnight. The resulting suspension was quenched withwater (10 mL) and extracted with EtOAc (3x20 mL). The combined organic layers were dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified by chromatography over silica gel (irregular SiOH; 15-40 jim; 12 g; gradient: from 100% heptane to 90% EtOAc, 10% MeOH (+5% NH4OH)). The pure fractions were collected and the solvent was evaporated to give 127 mg (39%, brownsolid) of intermediate 58.
  • 17
  • [ 1029684-37-4 ]
  • 1-[3-([1-chloro-8-methoxy-5-[(4-methylbenzene)sulfonyl]-5H-pyrido [4,3-b]indol-7-yl]oxy)propyl]pyrrolidine [ No CAS ]
  • 8-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl)-5-tosyl-5H-pyrido[4,3-b]indole [ No CAS ]
YieldReaction ConditionsOperation in experiment
61% With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In 1,4-dioxane; water at 100℃; for 16h; Inert atmosphere; 84.1 Step 1 Into a 50-mL round-bottom flask, was placed 1-(3-[[1-chloro-8-methoxy-5-(4-methylbenzenesulfonyl)-5H-pyrido[4,3-b] indol-7-yl] oxy]propyl)pynolidine (200 mg, 0.39 mmol, 1eq.), dioxane (5 mL), water (1 mL), 1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1H-imidazole (130 mg, 0.47 mmol, 1.20 eq.), K2C03 (161 mg, 1.17 mmol, 3.00 eq.), Pd(PPh3)4 (23 mg, 0.02 mmol, 0.05 eq.). The resulting solution was stined for 16 hr at 100°C under N2. The reaction mixtures were combined and concentrated under vacuum. The product was subjected to reverse phasepreparative HPLC (Waters SunFire column, 19 x 150 mm; gradient elution of 20% MeCN in water to30% MeCN in water over a 10 mm period, where both solvents contain 0.05% TFA) to provide 8-methoxy-7-(3-(pynolidin- 1 -yl)propoxy)- 1 -(1 -(tetrahydro-2H-pyran-2-yl)- 1 H-imidazol-5-yl)-5-tosyl-5H-pyrido[4,3-b]indole (150 mg, 6 1%). MS (ESI, pos. ion) mlz: 630.3 (M+1).
  • 18
  • [ 1029684-37-4 ]
  • (R)-4-(2-bromo-5-((S)-3-methylmorpholino)thiazolo[5,4-d]pyrimidin-7-yl)-3-methylmorpholine [ No CAS ]
  • (3S)-3-methyl-4-(7-((R)-3-methylmorpholino)-2-(1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl)thiazolo[5,4-d]pyrimidin-5-yl)morpholine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In water; acetonitrile at 150℃; for 0.75h; Microwave irradiation;
  • 19
  • [ 1029684-37-4 ]
  • (R)-4-(2-bromo-5-morpholinothiazolo[5,4-d]pyrimidin-7-yl)-3-methylmorpholine [ No CAS ]
  • (3R)-3-methyl-4-(5-morpholino-2-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine [ No CAS ]
YieldReaction ConditionsOperation in experiment
58% With chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) methyl-t-butyl ether adduct; potassium carbonate In water; acetonitrile at 150℃; for 1h; Microwave irradiation;
  • 20
  • [ 1029684-37-4 ]
  • 8-chloro-4-isopropoxy-2-(morpholin-4-yl)-1,7-naphthyridine [ No CAS ]
  • 4-isopropoxy-2-(morpholin-4-yl)-8-[1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-5-yl]-1,7-naphthyridine [ No CAS ]
YieldReaction ConditionsOperation in experiment
100% With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In 1,2-dimethoxyethane; water at 90℃; for 24h;
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1029684-37-4 ]

Organoboron

Chemical Structure| 2223006-68-4

[ 2223006-68-4 ]

1-(Tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.95

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Chemical Structure| 2223006-68-4

[ 2223006-68-4 ]

1-(Tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.95

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Esters

Chemical Structure| 2223006-68-4

[ 2223006-68-4 ]

1-(Tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.95

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Chemical Structure| 2223006-68-4

[ 2223006-68-4 ]

1-(Tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.95

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Related Parent Nucleus of
[ 1029684-37-4 ]

Imidazoles

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Tetrahydropyrans

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90

Chemical Structure| 1029684-36-3

[ 1029684-36-3 ]

2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Similarity: 0.90